Wednesday, February 10, 2010, 11:17AM AEST - The Australian Stockmarket closes in 4 hours and 48 minutes.
To create a watchlist or portfolio of shares, Register

Incyte Corporation (INCY)

 8:00AM AEST: 10.28 USD  Up 0.32 (3.21%)  
 MORE ON INCY 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Incyte Corporation (NGM:INCY) Delayed quote dataEdit
Last Trade:10.28 USD
Trade Time: 8:00AM AEST
Change:Up 0.32 (3.21%)
Prev Close:9.96
Open:10.23
Bid:10.25 x 100
Ask:10.40 x 2400
1y Target Est:12.25
Day's Range:10.07 - 10.45
52wk Range:1.96 - 11.24
Volume:2,102,388
Avg Vol (3m):3,322,070
Market Cap:1.22B
P/E (ttm):N/A
EPS (ttm):-1.76
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add INCY to Portfolio   Download Data

 HEADLINES 
•Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
Business Wire (Wed 8:10AM)
•Nektar adds to board of directors
at bizjournals.com (Wed, Feb 3)
•Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011
Business Wire (Fri, Jan 29)
•Eli Lilly Misses by a Penny
Zacks.com (Fri, Jan 29)
•Another Deal for Novartis
Zacks.com (Thu, Jan 21)
•Incyte to Present at the 28th Annual JPMorgan Healthcare Conference
Business Wire (Wed, Jan 6)
•Analysts Name Top Biotech Stocks for 2010: BioBuzz
at TheStreet.com (Wed, Jan 6)
•Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
at Seeking Alpha (Thu, Dec 24)
•Pharma Spreads Holiday Cheer in Bevy of Biotech Deals
at Seeking Alpha (Thu, Dec 24)
•Lightning Round OT: Kinder Morgan Energy, Incyte and More
at CNBC (Thu, Dec 24)
•Another Deal for Incyte
Zacks.com (Wed, Dec 23)
•Some Incyte Into Why These Drugs Rock
at Motley Fool (Wed, Dec 23)
•Deal activity lifts US stocks
at FT.com (Tue, Dec 22)
•INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
EDGAR Online (Tue, Dec 22)
•Pharma's Holiday Shopping Spree
at CNBC (Tue, Dec 22)
•Incyte shares rise on Eli Lilly deal
AP (Tue, Dec 22)
•A Slew of New Deals Move Pharma Stocks
Indie Research (Tue, Dec 22)
More Headlines for INCY...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.61
EPS Est (in 2 years) (Dec-10) :-1.31
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices